Login / Signup

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.

Erkki SoiniOuti VirtanenSaku VäätäinenJean-Baptiste BrièreKevin BowrinAurelie Millier
Published in: Advances in therapy (2020)
RIV + ASA was a cost-effective treatment alternative compared with ASA in patients with CCS or symptomatic PAD in Finland.
Keyphrases
  • peripheral artery disease
  • coronary artery disease
  • coronary artery
  • atrial fibrillation
  • replacement therapy